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Abstract Important homologies in the topology of the catalytic
site and the mechanism of action of thermolysin and neprilysin
have been evidenced by site-directed mutagenesis. The determi-
nation of differences in transition state stabilization between
these peptidases could facilitate the design of specific inhibitors.
Thus, two residues of thermolysin which could be directly
(Tyr157) or indirectly (Asp226) involved in the stabilization of the
transition state and their putative counterparts in neprilysin
(Tyr625 and Asp709) have been mutated. The results show that
Tyr157 is important for thermolysin activity while Tyr625 has no
functional role in neprilysin. Conversely, the mutation of Asp226
induced a slight perturbation of thermolysin activity while Asp709
in neprilysin seems crucial in neprilysin catalysis. Taken together
these data seem to indicate differences in the transition state
mode of stabilization in the two peptidases.
z 1998 Federation of European Biochemical Societies.
Key words: Neprilysin; Thermolysin;
Site-directed mutagenesis ; Molecular modeling
1. Introduction
Neprilysin (EC 3.4.24.11, NEP) is a member of the M13
family from the MA clan of zinc metallopeptidases [1]. In
addition to the active site consensus sequence HExxH, where
the histidines are two of the zinc ligands and the glutamate is
involved in the catalytic mechanism, enzymes of the M13
family are characterized by a second consensus sequence
ExxxD, where the glutamate is the third ligand of the zinc
ion and the aspartate is involved in the stabilization of the
active site [2]. Studies of the subsite speci¢city of neprilysin,
using various substrates and inhibitors, have shown that this
enzyme has signi¢cant analogies with the bacterial zinc metal-
lopeptidase thermolysin (EC 3.4.24.27) [2].
Thermolysin, a thermostable neutral protease produced by
the genus Bacillus thermoproteolyticus [3], belongs to the M4
family of the MA clan of zinc metallopeptidases. The co-crys-
tallization of thermolysin with several inhibitors has made it
possible to propose an enzymatic mechanism that has been
generalized to all the enzymes of this clan (review in [4]).
Neprilysin was ¢rst cloned in 1987 [5]. It is a type II mem-
brane protein expressed in many tissues including kidney and
central nervous system and is involved in the catabolism of
active peptides such as the atrial natriuretic peptide and en-
kephalins (review in [2]). Neprilysin inhibitors are of great
interest since they show anti-nociceptive and anti-hypertensive
properties [2].
Despite a weak homology between the primary sequences of
these two enzymes, there are signi¢cant secondary structure
similarities between thermolysin and the C-terminal portion of
neprilysin [6]. This allowed the identi¢cation by site-directed
mutagenesis of several residues in the active site of neprilysin.
Among those the three zinc ligands have been identi¢ed as
His583, His587 and Glu646 (His142, His146 and Glu166 in ther-
molysin) [7,8]. Glu584 (Glu143 in thermolysin) was proposed to
be involved in catalysis [9] by polarizing the attacking water
molecule. His711 (His231 in thermolysin) has been shown to be
involved in the stabilization of the transition state [10]. Asp650
(Asp170 in thermolysin) belongs to the second consensus se-
quence [11] and is H bonded to both His583 (His142 in ther-
molysin) and Arg717 (Arg203 in thermolysin) [12]. Moreover,
these residues are involved in a large hydrogen bond network
important for the stabilization of the active site and catalytic
activity [12]. These results have been used to build a three-
dimensional model of the C-terminal domain of neprilysin,
which includes the active site of the enzyme. Fig. 1 is a sche-
matic representation of the active site of thermolysin accord-
ing to the crystallographic data, the corresponding residues in
the reconstituted active site of neprilysin are given in italics. In
this model, based on sequence alignments, it has been sug-
gested that Tyr625 of neprilysin could have a role similar to
that of Tyr157 of thermolysin which is proposed to be involved
in the stabilization of the transition state [4] (Fig. 1). More-
over, Asp709 of neprilysin seems to be the counterpart of
Asp226 in thermolysin, which participates in the stabilizing
hydrogen bond network by interacting with His231 (Fig. 1).
To verify these hypotheses and improve the characteriza-
tion of neprilysin’s mechanism of action, comparative muta-
tions were performed on both enzymes: Tyr157 of thermolysin
and Tyr625 of neprilysin were mutated to phenylalanine, and
Asp226 of thermolysin and Asp709 of neprilysin to alanine. The
enzymatic and inhibitor binding properties of the mutants
were analyzed in terms of homologies or di¡erences in their
structures and mechanisms of action. The results were also
compared to those obtained previously in enzymes belonging
to other families of zinc metallopeptidases.
2. Materials and methods
2.1. Materials
Restriction and modifying enzymes, bacterial culture media and the
QuickChange Site Directed Mutagenesis kit were respectively from
New England Biolabs, Bio 101 and Stratagene obtained from Ozyme
(France). The Thermo Sequenase enzyme (United States Biochemical)
and [K-33P]ddNTP was purchased from Amersham (France). Cell cul-
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ture products were from Life Technologies (France). mAbs Alb1 and
T1 were generous gifts from Dr. C. Boucheix (Villejuif, France) and
Dr. C. Bohuon (Villejuif, France) respectively. Oligonucleotides were
synthesized by Genosys (UK). Leucine enkephalin (tyrosyl-glycyl-
glycyl-phenylalanyl-leucine), D-Ala2-leucine enkephalin (tyrosyl-D-
alanyl-glycyl-phenylalanyl-leucine) and glycyl-D-phenylalanine (Gly-
D-Phe) were purchased from Bale Biochimie (France). [3H]Leucine
enkephalin and [3H]D-Ala2-leucine enkephalin were purchased from
Izinta (Hungary). CNBr-activated Sepharose 4B resin was purchased
from Pharmacia (France) and bestatin, phosphoramidon and capto-
pril were from Sigma (France). The inhibitors thiorphan [13] and
HACBO-Gly [14] were prepared in the laboratory following reported
procedures.
2.2. Vector construction and site-directed mutagenesis
The Bacillus strain used was B. subtilis DB117, lacking neutral
protease activity [15]. The previously described pTLN-Mat3 plasmid
[12] encoding the sequence of the mature enzyme was used for double
strand mutagenesis in Escherichia coli. The mutated sequence EcoRI/
MluI was then subcloned in pTLN2 encoding the full length of the
enzyme to express the enzymes in B. subtilis DB117 as described
before [16]. For plasmid transformation, B. subtilis protoplasts were
prepared as described [17]. Puri¢cation of large-scale plasmid prepa-
rations was achieved using a modi¢ed polyethylene glycol precipita-
tion method [18]. The plasmid pcDNA-NEP has been previously de-
scribed [12].
Double strand mutagenesis was carried out using the QuickChange
Site Directed Mutagenesis kit following the manufacturer’s instruc-
tions. Oligonucleotides were designed to replace Asp226 in thermolysin
and Asp709 in neprilysin by an alanine, and Tyr157 in thermolysin and
Tyr625 in neprilysin by a phenylalanine. The authenticity of each mu-
tation was con¢rmed by sequencing the complete coding sequence.
2.3. Expression and puri¢cation of wild type and mutated thermolysins
B. subtilis DB117 cells harboring the plasmid pTLN2 were grown in
L-Broth containing 5 mM CaCl2 and 5 Wg/ml chloramphenicol, at
37‡C with shaking (180 rpm) for 16 h. Wild type and mutated en-
zymes were puri¢ed from the culture supernatant by a⁄nity chroma-
tography using a column of Gly-D-Phe, coupled to CNBr-activated
Sepharose 4B resin as described previously [16].
2.4. Cell culture and transfection
COS cells were grown in Dulbecco’s modi¢ed Eagle’s medium sup-
plemented with 10% (v/v) fetal calf serum and 50 Wg/ml gentamicin at
37‡C. One day before transfection cells were seeded into 10 cm Petri
dishes, at a density of 106 cells/dish. Cells were transfected with the
pcDNA-NEP vector encoding wild type or mutant neprilysin, using a
DEAE-dextran-chloroquine method [19]. 48 h after transfection, cells
were solubilized at a protein concentration of 1 mg/ml in 50 mM Tris-
HCl, pH 7.4 containing 1% (w/v) n-octyl glucoside for 30 min on ice.
The preparation was then centrifuged at 20 000Ug for 15 min and the
supernatant was used for enzymatic assays.
2.5. Western blotting
Proteins were subjected to 8% (neprilysin) or 12% (thermolysin)
SDS-PAGE and blotted onto nitrocellulose ¢lters. The blots were
sequentially incubated with mAb Alb1 raised against human neprily-
sin or mAb T1 raised against thermolysin and with an anti-mouse Ig,
horseradish peroxidase-linked antibody (Amersham, France). The
peroxidase activity was revealed with the ECL detection kit from
Amersham (France).
2.6. Enzyme assays
Thermolysin activity and Ki values of inhibitors were determined as
previously described [16,20] using 20 nM of [3H]leucine enkephalin as
a substrate. Km and kcat values were determined by the isotopic dilu-
tion method. Neprilysin activity and Ki values of inhibitors were
measured as previously described using 40 nM [3H]D-Ala2-leucine
enkephalin as substrate [21]. Km values were determined by the iso-
topic dilution method. In both cases calculations were done using the
program ENZFITTER (Biosoft). In order to determine the kcat values
the neprilysin levels were evaluated by dot blot using recombinant
human neprilysin as standard (generously provided by Khepri Phar-
maceuticals, USA) [12]. IC50 values were considered to be equal to Ki
values as the concentrations of substrates used were much lower than
Km values. In all cases the reactions were stopped when substrate
degradation was 910%.
3. Results
3.1. Expression of wild type and mutated enzymes
Wild type and mutant thermolysins were puri¢ed from the
culture supernatant of B. subtilis DB117 using a Gly-D-Phe
a⁄nity column with yields of approximately 5 mg/l for wild
type enzyme, and 0.5 mg/l for D226A and Y157F. Thermolysin
is expressed as a pre-proenzyme and we have previously
shown that its maturation necessitates an autocatalytic and
intramolecular cleavage of the precursor pro-thermolysin
[22] accounting for the lower yields obtained in the case of
the mutants. Western blot analysis, with mAb T1, showed an
apparent molecular mass for the three enzymes of 36 kDa
(Fig. 2A).
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Fig. 1. Schematic representation of the active site of thermolysin. The apparent network of hydrogen bonds between the residues involved in
catalysis is represented by broken lines. The numbers of the corresponding residues in the neprilysin active site are given in italics.
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The wild type and mutated neprilysins were expressed in
COS cells, and analyzed by immunoblotting. As seen in Fig.
2B, wild type, D709A and Y625F neprilysin migrated with the
same apparent molecular mass (98 kDa) and had the same
level of expression indicating that the mutation did not inter-
fere with the biosynthesis of neprilysin. Correct glycosylation
of the enzymes was veri¢ed by endoglycosidase H and N-gly-
cosidase F digestion (data not shown).
3.2. Kinetic parameters of the tyrosine mutants in thermolysin
and neprilysin
Mutation Y157F in thermolysin a¡ected mainly the kcat val-
ue (63-fold diminution) (Table 1). The speci¢c activity of this
mutant is then reduced 92-fold as compared to that of the
wild type enzyme. The proposed counterpart of this tyrosine
in neprilysin is Tyr625. When this residue was mutated to
phenylalanine only a slight increase in the Km value was ob-
served with no change in the kcat value (Table 1). The result-
ing kcat/Km ratio is 2.9-fold lower than that of the wild type
enzyme.
3.3. Inhibition studies with the tyrosine mutants in thermolysin
and neprilysin
In the case of the Y157F mutant in thermolysin the Ki value
for the thiol inhibitor thiorphan is increased by a factor of 3.4
while that of the hydroxamate inhibitor HACBO-Gly is in-
creased 10-fold. Since these two inhibitors di¡er only in the
nature of the zinc ligand it seems that the e¡ect observed may
be due to the mode of binding to the zinc ion (monodentate
with a thiol and bidentate for an hydroxamate). The Ki value
of the transition state analogue phosphoramidon is increased
by a factor of 3 similar to that of the ‘collected product’
analogue thiorphan. When Tyr625 was mutated to phenylala-
nine in neprilysin the only di¡erence observed in the Ki values
of the inhibitors tested was a 5.5-fold increase in the case of
phosphoramidon (Table 2).
3.4. Kinetic parameters of the aspartate mutants in thermolysin
and neprilysin
In the case of the D226A mutant in thermolysin the Km
value is increased by 9.4-fold and the kcat is decreased 4-
fold (Table 1). The kcat/Km ratio is decreased by 39-fold as
compared to the wild type enzyme. When the proposed coun-
terpart of this aspartate was mutated in neprilysin (Asp709),
the Km value obtained was similar to that of the wild type
enzyme while the kcat value was dramatically decreased (a
factor of 319). The resulting speci¢c activity is thus decreased
by a factor of 298 as compared to the wild type enzyme.
3.5. Inhibition studies with the aspartate mutants in thermolysin
and neprilysin
In the case of the D226A mutant of thermolysin the e¡ects
observed are an 8-fold and a 6-fold increase of the Ki values
in the case of thiorphan and HACBO-Gly (Table 2). Interest-
ingly, the Ki of phosphoramidon is only increased by a factor
of 3. When the proposed counterpart of this aspartate was
mutated in neprilysin the resulting mutant D709A showed dra-
matic decreases in the inhibitory potencies of the inhibitors
tested (Table 2). The increase in Ki value was of 7.5U103 in
the case of thiorphan and s 104 in the case of phosphorami-
don. Interestingly, when the zinc ligand is a hydroxamate
(HACBO-Gly) the factor is only 3.6.
4. Discussion
In order to design new potent and selective inhibitors of
neprilysin it is important to have a precise idea of its active
site organization. In the absence of crystallographic data on
this enzyme site-directed mutagenesis studies, in association
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Table 1
Kinetic constants for the hydrolysis of leucine enkephalin by wild type, Y157F and D226A thermolysins and for the hydrolysis of D-Ala2-Leucine
enkephalin by wild type, Y625F and D709A neprilysins
Enzyme Km (WM) kcat (min31) kcat/Km (WM31 min31)
Thermolysin Wild type 210 þ 25 9329 þ 754 44.4
Y157F 480 þ 26 100 þ 2 0.21
D226A 1985 þ 54 2252 þ 87 1.13
Neprilysin Wild type 55 þ 6 1149 þ 144 20.9
Y625F 141 þ 14 1003 þ 46 7.1
D709A 47 þ 6 3.6 þ 0.27 0.07
Reactions were carried out as described in Section 2. Data are means þ S.E.M. from at least three independent determinations.
Fig. 2. Analysis of wild type and mutated enzymes by Western blots
as described in Section 2. A: Lane 1, wild type thermolysin; lane 2,
Y157F mutant; lane 3, D226A mutant. B: Lane 1, wild type neprily-
sin; lane 2, Y625F mutant; lane 3, D709A mutant.
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with molecular modeling, remain useful tools to investigate
the functional roles of speci¢c residues in the neprilysin active
site. Thermolysin is the model of active site for neprilysin and
previous studies have already proved the similarities between
the two active sites [7^12]. In this work we studied residues
implicated directly or not in the transition state stabilization
of these two enzymes. Tyr157 is proposed to be implicated,
with His231, in the stabilization of the transition state as de-
duced from the crystallographic structure of thermolysin-in-
hibitor complexes [4] and Tyr625 in neprilysin has been pro-
posed to be the counterpart of Tyr157 in thermolysin
according to sequence alignments [23]. The two tyrosines
were mutated to phenylalanine in order to alter as little as
possible the organization of the active sites. The recent
achievement of a three-dimensional model of neprilysin active
site (Tiraboschi, personal communication) makes it possible
to propose Asp709 of neprilysin as the equivalent of Asp226 of
thermolysin which stabilizes His231 by a hydrogen bond. In
both enzymes the aspartate residues were mutated to alanine
to abolish this interaction.
The decrease in kcat/Km value observed with the mutant
Y157F in thermolysin (200-fold) is consistent with the crystal-
lographic data and the proposed role of this residue in the
stabilization of the transition state [4]. His231 was also impli-
cated in the stabilization of the transition state [4]. However,
when this residue was mutated in thermolysin [24], a dramatic
500-fold decrease in the kcat value was observed suggesting
that the role of Tyr157 in the stabilization of the transition
state is slightly less important than that of His231. Moreover,
the e¡ects observed on the Ki values of the inhibitors tested
were smaller than those obtained with His231. In the case of
the mutation of His231 in phenylalanine in thermolysin the
decrease in inhibitory potency of phosphoramidon was
s 104 [24]. This di¡erence may be consistent with a minor
role of Tyr157 in the stabilization of the transition state as
compared to His231. It could be observed that in the crystal-
lized complexes of thermolysin with inhibitors mimicking the
transition state, His231 is involved in all cases in the stabiliza-
tion of this intermediate, but Tyr157 is found in only some
examples such as phosphoramidon, ZFPLA or CLT [4].
This seems to indicate that this interaction is not predominant
for the binding of these inhibitors. This was con¢rmed here by
the slight modi¢cation observed in the Ki value of phosphor-
amidon in the Y157F mutant enzyme. However, the important
perturbation induced by this mutation in the catalytic process
indicates that the inhibitors crystallized to date with thermo-
lysin could represent structural models for di¡erent steps in
the catalysis, but are not ‘real’ intermediates.
When Tyr625 was mutated to phenylalanine in neprilysin the
kinetic parameters and Ki values of the inhibitors tested were
similar to those of the wild type enzyme. These results suggest
that either this tyrosine is not the equivalent of Tyr157 in
thermolysin or Tyr625 in neprilysin is equivalent to Tyr157 of
thermolysin but does not have a role in the stabilization of the
transition state. Sequence alignments of the neprilysins (Kell,
ECE-1, ECE-2, PEX and Pepo) show that this tyrosine is
conserved in all the enzymes except in Pepo where it is re-
placed by a phenylalanine [25^30]. This could indicate that
this residue does not have a signi¢cant role in the M13 family
of zinc metallopeptidases as compared to thermolysin. It is
also interesting to compare these results with those obtained
when the residues assumed to be the equivalents of Tyr157
were mutated in other zinc metallopeptidases. The mutation
of Tyr683 in ECE-1 (personal communication), which is anal-
ogous to Tyr157 of thermolysin according to sequence align-
ments, showed that this residue does not play any role in the
enzymatic activity of this enzymes as observed here for nepri-
lysin. In the case of human testicular angiotensin converting
enzyme (ACE) (Tyr200) a slight e¡ect has been reported on the
kcat while no e¡ect was found in rabbit testicular ACE
(Tyr236) [31,32]. Conversely, the mutation of Tyr471 in APA
[33] induced a large decrease in the kcat value of the mutated
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Table 2
Ki values of inhibitors for the wild type and mutated thermolysins and neprilysinsa
aData are means þ S.E.M. from at least three independent determinations.
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enzyme. Taken together these results seem to indicate that an
evolution in the structure of the active sites, and consequently
in the mechanism of action, of the di¡erent families of zinc
metalloenzymes could have occurred. In thermolysin family
two residues (His231 and Tyr157) are involved in the stabiliza-
tion of the transition state. In neprilysin, ECE and ACE fam-
ilies, only a histidine residue seems to have such a function.
The aminopeptidase family seems to be more related to the
astacin family in which only a tyrosine residue is involved in
the stabilization of the transition state [34].
In the case of the mutant D226A a large decrease in speci¢c
activity of thermolysin is observed, due to a modi¢cation of
both the kcat and Km values. In the structure of thermolysin
this aspartate is involved in a hydrogen bond with His231
which stabilizes the transition state [24] and the modi¢cations
observed here in the kinetic parameters are less important
than those obtained when His231 was mutated. The decrease
in speci¢c activity of the D226A mutant cannot be attributed
to a direct e¡ect of the mutation but rather to an indirect
e¡ect. In fact, the presence of an alanine at this position
preventing the formation of the hydrogen bond with His231
probably leads to a move of this residue and a less e⁄cient
stabilization of the transition state by a local perturbation of
the H bond network.
The mutant D709A in neprilysin also showed a large de-
crease in speci¢c activity (300-fold) due only to a large de-
crease in the kcat value. Curiously, this e¡ect is signi¢cantly
greater than that previously obtained when His711 in neprily-
sin was mutated in glutamine or phenylalanine [10] where the
kcat value was only decreased by a factor of 40. The e¡ects
obtained with these AspCAla mutations on the Ki values of
the inhibitors are also very di¡erent in both enzymes. In ther-
molysin these e¡ects are very low as compared to those obtain
in neprilysin when Asp709 was mutated. From these data, it
could be proposed that in neprilysin the main role of Asp709 is
to stabilize the structure of the active site by preserving the
right position of His711 as unique proton donor in the tran-
sition state. This could explain the large perturbation in nep-
rilysin activity induced by the absence of Asp709. In the case of
thermolysin, it could be proposed that the perturbation of the
hydrogen bond network associated with the D226A mutation
could induce a slight reorganization of the active site in the
vicinity of His231. This perturbation is not highly detrimental
for catalysis since the presence of Tyr157 could counterbalance
the loss of e⁄ciency of His231 in the stabilization of the tran-
sition state.
In conclusion, these results have again con¢rmed that the
organization of the catalytic sites of thermolysin and neprily-
sin is very similar. However, although the overall mechanisms
of action are similar, the mode of stabilization of the transi-
tion state di¡ers between the two enzymes. These results also
con¢rmed the importance of hydrogen bond networks in the
active sites of both enzymes yet their importance and inter-
dependence are not the same.
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